iScience (Nov 2024)
High glycemic variability is associated with a reduced T cell cytokine response to influenza A virus
- Marcus Z.W. Tong,
- Katina D. Hulme,
- Soi Cheng Law,
- Ellesandra Noye,
- Emily S. Dorey,
- Keng Yih Chew,
- Louise C. Rowntree,
- Carolien E. van de Sandt,
- Katherine Kedzierska,
- Marco Goeijenbier,
- Katharina Ronacher,
- Fawaz Alzaid,
- Jean-Baptiste Julla,
- Jean-Pierre Riveline,
- Katie E. Lineburg,
- Corey Smith,
- Emma J. Grant,
- Stephanie Gras,
- Linda A. Gallo,
- Helen L. Barrett,
- Kirsty R. Short
Affiliations
- Marcus Z.W. Tong
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia
- Katina D. Hulme
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
- Soi Cheng Law
- Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia
- Ellesandra Noye
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia
- Emily S. Dorey
- Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia
- Keng Yih Chew
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia
- Louise C. Rowntree
- Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia
- Carolien E. van de Sandt
- Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
- Katherine Kedzierska
- Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia
- Marco Goeijenbier
- Department of Intensive Care, Erasmus MC, Rotterdam, the Netherlands; Department of Intensive Care, Spaarne Gasthuis, Haarlem, Hoofddorp, the Netherlands
- Katharina Ronacher
- Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia; Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, Australia
- Fawaz Alzaid
- Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Dasman Diabetes Institute, Kuwait, Kuwait
- Jean-Baptiste Julla
- Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
- Jean-Pierre Riveline
- Université Paris Cité, CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
- Katie E. Lineburg
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- Corey Smith
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Queensland Immunology Research Centre, St Lucia, QLD, Australia
- Emma J. Grant
- Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, Bundoora, VIC, Australia; Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia
- Stephanie Gras
- Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, Bundoora, VIC, Australia; Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia
- Linda A. Gallo
- School of Health and Behavioural Sciences, University of the Sunshine Coast, Petrie, QLD, Australia
- Helen L. Barrett
- Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia; University of New South Wales Medicine, Kensington, NSW, Australia; Obstetric Medicine, Royal Hospital for Women, Randwick, NSW, Australia
- Kirsty R. Short
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia; Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, Australia; Queensland Immunology Research Centre, St Lucia, QLD, Australia; Corresponding author
- Journal volume & issue
-
Vol. 27,
no. 11
p. 111166
Abstract
Summary: Diabetes mellitus significantly increases the risk of severe respiratory virus disease like influenza and COVID-19. Early evidence suggests that this susceptibility to respiratory viral disease is driven by glycemic variability, rather than average blood glucose levels. Here, we use blood samples and constant glucose monitoring (CGM) data obtained from people living with type 1 diabetes (T1D) to determine the effects of glycemic variability on the ex vivo T cell response to influenza virus. We show that high glycemic variability in participants living with T1D is associated with a reduced proportion of CD8+CD107a−IFNγ−MIP1β−TNF+ T cells in response to stimulation with influenza virus and an influenza virus peptide pool. Thus, this study provides evidence that glycemic variability affects the ex vivo T cell response to respiratory viruses. These data suggest that monitoring glycemic variability may have important implications in understanding the antiviral immune response in people with diabetes.
